

Caal.

- (b) amino acids 2 to 331 of SEQ ID NO:2 or the complete amino acid sequence excepting the N-terminal methionine encoded by the cDNA clone contained in ATCC Deposit No. 97343;
 - (c) amino acids 24 to 331 of SEQ ID NO:2;
 - (d) amino acids 27 to 331 of SEQ ID NO:2; and
- (e) the amino acid sequence of the mature form of Neuronal Attachment Factor-1 (NAF-1) encoded by the cDNA clone contained in ATCC Deposit No. 97343;

wherein said polypeptide promotes neuronal cell adhesion or axonal neurite extension.



- 28. (Once amended) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - (a) amino acids 1 to 331 of SEQ ID NO:2;
- (b) the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97343;
 - (c) amino acids 2 to 331 of SEQ ID NO:2,
- (d) the complete amino acid sequence excepting the N-terminal methionine encoded by the cDNA clone contained in ATCC Deposit No. 97343;
 - (e) amino acids 24 to 331 of SEQ ID NO:2;
 - (f) amino acids 27 to 331 of SEQ ID NO:2; and
- (g) the amino acid sequence of the mature form of NAF-1 encoded by the cDNA clone contained in ATCC Deposit No. 97343.
- 29. (Once amended) The isolated polypeptide of claim 28 wherein said amino acid sequence is (a).
- 30. (Once amended) The isolated polypeptide of claim 28 wherein said amino acid sequence is (b).
- 31. (Once amended) The isolated polypeptide of claim 28 wherein said amino acid sequence is (c).

2

App. No. 09/170,042


Atty. Docket No. PF226D1



- The isolated polypeptide of claim 28 wherein said 32. (Once amended) amino acid sequence is (d).
- The isolated polypeptide of claim 28 wherein said 33. (Once amended) amino acid sequence is (e).
- The isolated polypeptide of claim 28 wherein said (Once amended) 34. amino acid sequence is (f).
- The isolated polypeptide of claim 28 wherein said (Once amended) 35. amino acid sequence is (g).
- epitope-bearing portion of the NAF-1 (Once amended) 36. An polypeptide consisting of at least 9 contiguous amino acids of SEQ ID NO:2.
- The epitope-bearing portion of claim 36, which 37. (Once amended) consists of at least 15 contiguous amino acids of SEQ ID NO:2.
- The epitope-bearing portion of claim 36, wherein 38. (Once amended) said portion consists of at least amino acids 75 to 100 of SEQ ID NO:2.
- 39. (Once amended) The epitope-bearing portion of claim 36, wherein said portion consists of at least amino acids 168 to 180 of SEQ ID NO:2.
- The epitope-bearing portion of claim 36, wherein 40. (Once amended) said portion consists of at least amino acids 204 to 226 of SEQ ID NO:2.
- The epitope-bearing portion of claim 36, wherein 41. (Once amended) said portion consists of at least amino acids 258 to 281 of SEQ ID NO:2.

App. No. 09/170,042

Atty. Docket No. PF226D1



Cort.

- 43. (Once amended) An isolated polypeptide consisting of at least 10 contiguous amino acids of SEQ ID NO:2.
- 44. (Once amended) The isolated polypeptide of claim 43, which has at least one activity selected from the group consisting of:
 - (a) promotes axonal neurite extension;
 - (b) promotes neural cell adhesion; or
 - (c) binds to an antibody specific to the polypeptide of SEQ ID NO:2.

C3

- 48. (Once amended) The isolated polypeptide of claim 43, which consists of at least 30 contiguous amino acids of SEQ ID NO:2.
- 49. (Once amended) The isolated polypeptide of claim 43, which consists of at least 50 contiguous amino acids of SEQ ID NO:2.
- 58. (Once amended) A composition comprising the polypeptide of claim 21 and a carrier.

- 59. (Once amended) A composition comprising the polypeptide of claim 36 and a carrier.
- 60. (Once amended) A composition comprising the polypeptide of claim 43 and a carrier.